Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy.

As a hallmark of solid tumors, hypoxia promotes tumor growth, metastasis, and therapeutic resistance by regulating the expression of hypoxia-related genes. Hypoxia also represents a tumor-specific stimulus that has been exploited for the development of bioreductive prodrugs and advanced drug delivery systems. Cell division cycle 20 (CDC20) functions as an oncogene in tumorigenesis, and we demonstrated the significant upregulation of CDC20 mRNA in the tumor vs. paratumor tissues of breast cancer patients and its positive correlation with tumor hypoxia. Herein, a hypoxia-responsive nanoparticle (HRNP) was developed by self-assembly of the 2-nitroimidazole-modified polypeptide and cationic lipid-like compound for delivery of siRNA to specifically target CDC20, a hypoxia-related pro-tumorigenic gene, in breast cancer therapy. The targeted delivery of siCDC20 by HRNP sufficiently silenced the expression of CDC20 and exhibited potent antitumor efficacy. We expect that this strategy of targeting hypoxia-correlated pro-tumorigenic genes by hypoxia-responsive RNAi nanoparticles may provide a promising approach in cancer therapy.

[1]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[2]  R. Altman,et al.  Investigating hypoxic tumor physiology through gene expression patterns , 2003, Oncogene.

[3]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[4]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Rankin,et al.  The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.

[6]  Y. Furukawa,et al.  CDC20, a potential cancer therapeutic target, is negatively regulated by p53 , 2008, Oncogene.

[7]  C. Parker,et al.  The relevance of a hypoxic tumour microenvironment in prostate cancer , 2010, BJU international.

[8]  M. Malumbres,et al.  Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. , 2010, Cancer cell.

[9]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[10]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[11]  Robert Langer,et al.  Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug , 2013, Proceedings of the National Academy of Sciences.

[12]  Zhiwei Wang,et al.  Cdc20: a potential novel therapeutic target for cancer treatment. , 2013, Current pharmaceutical design.

[13]  A. Letai,et al.  APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. , 2014, Developmental cell.

[14]  P Kronqvist,et al.  Cdc20 and securin overexpression predict short-term breast cancer survival , 2014, British Journal of Cancer.

[15]  Timothy B Sackton,et al.  Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C , 2014, Nature.

[16]  S. Biswas,et al.  Hypoxia-targeted siRNA delivery. , 2014, Angewandte Chemie.

[17]  Ick Chan Kwon,et al.  Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. , 2014, Biomaterials.

[18]  Zhiwei Wang,et al.  Targeting Cdc20 as a novel cancer therapeutic strategy. , 2015, Pharmacology & therapeutics.

[19]  Zhen Gu,et al.  Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery , 2015, Proceedings of the National Academy of Sciences.

[20]  J. Park,et al.  Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives. , 2016, Chemical communications.

[21]  Wei Huang,et al.  An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome. , 2016, Acta biomaterialia.

[22]  Zhen Gu,et al.  Light‐Activated Hypoxia‐Responsive Nanocarriers for Enhanced Anticancer Therapy , 2016, Advanced materials.

[23]  Jonathan Rasmussen,et al.  Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. , 2017, Nano letters.

[24]  J. Park,et al.  Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery. , 2017, International journal of biological macromolecules.

[25]  Yuzhuo Wang,et al.  Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. , 2018, Angewandte Chemie.

[26]  I. Amelio,et al.  The hypoxic tumour microenvironment , 2018, Oncogenesis.

[27]  D. Oupický,et al.  Advances in Stimulus‐Responsive Polymeric Materials for Systemic Delivery of Nucleic Acids , 2018, Advanced healthcare materials.